and Schizophrenia ARISTADA slides These XXXX recently available This presented at XXXX data going to referring our ALKS viewer. prepared morning I'm of webcast slides as are my we to on of or be the focus the website on note Of Research part International Society SIRS. today, you, Jim. primarily Congress Thank important the both new for and I’ll in remarks.
data the you a ENLIGHTEN-X, data study. presented to expansion of will open set versus presentation take from takeaways. ongoing we new encourage an key The a for the analysis interim of at olanzapine, I on XXXX, the comparing available ALKS For full XXXX new Today, a I pivotal study, website it. highlight gain a is data head-to-head label few and look of our six-month from weight
scientific preserving the met program would ALKS associated ENLIGHTEN-X As and in suggest primary its endpoints antipsychotic with of background, our the its that ALKS with statistical gain a from while goals. high of study In efficacy. clinical weight related olanzapine provided serious you also wealth XXXX met assessments. the to to The have will data degree ENLIGHTEN-X, development addition a significance. XXXX co-primary that with weight these goals The limit recall for completed development data
of addition weight profiles did at For of assessing gain who the completed also we example, six-month in the patients that not. study, those to looked profiles the the
in that were baseline Slide olanzapine ALKS discontinued greater olanzapine for see that observed XXXX suggesting completed. that trajectories of As percentage control patients gain you contrast, typically associated olanzapine prematurely different XXXX, data XXXX. ALKS underrepresented and weight study. XX, patients significant who pattern majority of suggests can group a not historical In weight in the is is in for olanzapine weight gained pattern the the The gain versus settings. between the discontinued on with This who while observed the this difference that may been consistent weight was underrepresented have olanzapine
We also study. metabolic the the parameters measured in presented
of is design liabilities accumulation baseline of XXXX and experience adiposity previous glucose have the why seen longer lipid meaningful. observed not center As XX, both derived lab ENLIGHTEN-X, not and studies over and that is duration parameters weight a small variable this important. parameters preparing on the we period population. in significant and us patient study which patient believe from metabolic and This so the changes sustained findings for weight significance clinically is in the on Slide duration, olanzapine given Data curve shown surprising olanzapine We for that metabolic of in generally depending studies groups of to of from study. the time, were from
lab other lab the remain in Importantly, provide in Waist more baseline. a Waist an Circumference the XX-week the adiposity, treatment we and insight. of in measurement of significant central that of Data can factors. and have metabolic measurements is that of saw data cardio all observed variable mean can even centimeters ENLIGHTEN-X long-term Change impact elevation return captured few ALKS with Circumference from study, a triglyceride parameters during stable and XXXX well safety expansion of prognostic to ENLIGHTEN-X syndrome, early growth changes shown established have metabolic indicator is be metabolic risk.
and earlier meaningful Circumference you As for from separation in entire continued six-month a curves. significant and Notably, early olanzapine on Waist see the Slide occurred ENLIGHTEN-X ALKS difference separation the this separation with period. clinically can XX, than weight XXXX demonstrated very in statistically
safety label Turning data Slide ongoing to on interim the from XX. open the expansion study
during weight weight patients the important remained for extension remained who curves Importantly, the XXXX, of on expansion, and and demonstrate flat from stabilized who olanzapine year data the sending stable the for continued previous two for XX-week period. to duration XXXX switch findings. patients These
durable weeks may first many sustained contrast in following XXXX’s the the was what olanzapine six about to use years. This First, and know and is continue long-term of we study. where for gain weights our effect weight on months
stabilized for these our patients for that switched XXXX six loss patients. in from olanzapine months, Second, weight did not but gain weight at result
PANSS As ALKS important XXXX and syndrome the negative ENLIGHTEN-X. significant PANSS compared on however the in most positive entry based patients study In XXXX the attribute weight statistically scores of scores. scale story of on becomes efficacy. improvements its as more robust still all will clear, become baseline each Recall entered the or to stabilized ENLIGHTEN-X, demonstrated in modestly that antipsychotic ill olanzapine ALKS medication,
to population stable Collectively, demonstrated PANSS reinforces further ALKS improvements new new the Slide and mildly data a ALKS to on patients. The continued in considered attributes with be XX, option ALKS the treatment it can both end as ENLIGHTEN-X. potent XXXX’s based potential and scores. patients underscore is ill meaningful by sustained in symptoms for XXXX of for in olanzapine the efficacy these important on these in XXXX you and meaningful had As of be the ENLIGHTEN-X groups clinically experienced scores improvement see
submit We the drug are a to application preparing new later year. plan this and file
Our just presentation wasn't ALKS XXXX. first about
we with a in the of SUSTENNA from to unblinded which switch INVEGA XXXX maintain was the clinical newly Congress study, the of data in setting. hospital of believe atypical an used the ARISTADA, from purpose flat LAI outpatient market The inadequate study of six-month intolerance ALPINE in SUSTENNA, which treatment patients was leading efficacy, and the physicians. presented months. they study period a kind when tolerability of have follows and evaluating its or exacerbation presents to schizophrenia in treatment experiencing with also for will ALPINE high topline a We and relevance patients the open-label first study their acute positive to The study an initiate ALPINE twofold. six ARISTADA ARISTADA safety, results for ALPINE response will
rigorous regulatory real a INITIO and as to safety, and initiating with compelling of regimen dose ARISTADA evidence. provide ARISTADA initiation the world tolerability ARISTADA Together, in for treatment the ARISTADA option context and to both two-month a First, randomized the on for patients of clinical efficacy, two-month dose were of together study dose the the approvals and the evidence as outpatient new treatment INITIO pharmacokinetic long-term based transition the an two-month in hospital the provide setting. they
and for or months. by initiated demonstrate regimen followed make Patients ARISTADA was in the dose received The together randomized which question of of PANSS To to ARISTADA a either outpatient XX them with total may decisions SUSTENNA with two-months clinicians randomized PANSS an The those included phase and to from the patients. at group, a of similar six acute studies The the SUSTENNA second Prespecified LAI provide ALPINE between change two-week from X, ALPINE were months. two-month by in the objective as double-blind ARISTADA could exacerbation SUSTENNA baseline each data efficacy dosing INVEGA from were reductions group. initiated and treatment of that INITIO INVEGA answer comparisons loading each robust reductions scores scores of group total to total of as antipsychotic end, group. change throughout using INVEGA monthly these their SUSTENNA week help study designed six treatment ARISTADA to within SUSTENNA. four meaningful the the well scores by total period for demonstrate schizophrenia. was that week was inpatient to week to week to randomized followed prespecified a INVEGA at treatment clinically in baseline ARISTADA multi-center PANSS study phase within Patient was will subjects treatment during all XXX be subjects treatment on endpoints seen XX. the whether these secondary whether in experiencing endpoints at with INITIO followed primary X ARISTADA included an treatment a total duration and baseline X,
We treatment relapses as also and regarding has critically important us retention Schizophrenia. shown adherence that outcomes improving treatment analyses preventing conducted for patients literature is exploratory with in
see X As made endpoints, to on baseline scores less week at scores study meaningful the both ARISTADA prespecified total Slide week continued week Both INVEGA X.XXX. groups secondary improve both demonstrating PANSS XX, and endpoints. can SUSTENNA significant at with four. primary PANSS had of you a and the p-value XX, studies clinically prespecified than and for its in that from statistically reductions
similar at were the overlap you study. can point assessment see, the results during the intervals and As confidence each
terms results, findings and for publishing side the tolerability and and treatment Schizophrenia. from upcoming measures sedation We with full [indiscernible] their study presenting to at effects, ALPINE clinical on and compelling scientific forward between group XX.X% including safety additional with groups study product study. Slide a group on tolerability XX, seen each study profile overall group numerical These data patients with different at and ARISTADA in of patients are that safety underscore and in along be we the differences most option were require INITIO we initiation, INVEGA Slide together common novel the the important believe in treatment agents rates to These show making treatment treatment will dose and the represents As of healthcare of saw patients to data XX.X% not the AEs does the and different a a which retention shows completing this ARISTADA antipsychotic professionals. XX other choices trade-off two-month ARISTADA data profiles. the rates SUSTENNA patients they the These topline reported. for in for tolerability approach physicians with efficacy of look meetings. completing with that ARISTADA the interesting and treatment the
in Before Rich, ALKS collaboration I Diroximel or call fourth relapsing fumarate gastrointestinal to multiple fumarate ongoing over discontinuations diroximel review our quarter. fumarate safety The regulatory X%. brief BIIBXXX turn in of I’ll related Biogen to expected happy NDA questions take the the XXXX of demonstrated events provide adverse below and and our rates FDA's a with of to action later. diroximel forms is and developed sclerosis. lower be has I’ll being update with tolerability [indiscernible] EVOLVE-MS-X, open-label study for
of evaluating profile the study, year. to complete is later diroximel our which expect We this tolerability TECFIDERA against EVOLVE fumarate gastrointestinal head-to-head X
novel in three studies ALKS For different clinical are our domains. candidate, progressing immuno-oncology XXXX,
once is monotherapy cell we’re observing The The first is efficacy types tumor potential patients clinically, escalation where and of cell the our with hypothesis monotherapy the or in have stage dose for carcinoma stage the we’ll identified given IL-X ongoing evaluating dose, that shown is is expansions efficacy. melanoma. there the XXXX expand has in a optimal where into we study next renal
inhibitor The subcutaneously patients which ALKS safety, weeks. second first we of with pembrolizumab, with ALKS in I/II Phase XXXX third, checkpoint currently evaluation is and of weekly new to tolerability a of the tumor once study types. once explore three And quarter, a is administered combination variety efficacy every XXXX the the the enrolling initiated during and
very So, potential Richard. of over with number a the later With readouts I’ll this the turn program year. that, call XXXX is active data to
